Table 1Performance of physician process models treating 10,000 synthetic patients for 1 year

Cell designationaFeedbackFeedforward
WeakStrongWeakStrong
Percent to goal by cell (%)
LL84.694.898.4100.0
LH91.999.199.8100.0
ML9.826.526.590.5
MH20.642.949.598.4
HL0.00.00.044.5
HH0.00.05.087.3
Average costb to treat by cell ($)
LL8118661,2101,390
LH7918361,1651,325
ML1,6461,6972,0442,648
MH1,6391,6912,0082,303
HL1,9732,0452,5264,200
HH1,9612,0332,5243,839
Average final A1c by cell (%)
LL6.76.76.56.2
LH6.76.66.46.1
ML7.97.67.56.8
MH7.77.47.26.6
HL10.19.79.27.7
HH9.89.18.56.8
Percent encounters with errors by cell (%)
LL1.00.90.00.0
LH1.21.20.00.0
ML23.617.09.03.0
MH16.07.92.30.8
HL53.152.241.619.3
HH45.834.127.02.4
a

Cells are labeled using a 2-letter designator, where the first letter specifies initial A1c range (L, M, or H), and the second letter specifies level of patient adherence to treatment (L or H).

b

Average costs included prescription costs, charges for office visits, lab orders, and referrals to specialists; inpatient and emergency treatment costs were not included. Prescription costs were based on Average Wholesale Prices.17

From: Using Data Mining to Predict Errors in Chronic Disease Care

Cover of Advances in Patient Safety: New Directions and Alternative Approaches (Vol. 3: Performance and Tools)
Advances in Patient Safety: New Directions and Alternative Approaches (Vol. 3: Performance and Tools).
Henriksen K, Battles JB, Keyes MA, et al., editors.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.